Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study details that worldwide about 2% of the population identified as transgender in 2024 and highlights significant mental health improvements with gender-affirming medical interventions, such as decreased depression and gender dysphoria, and enhanced quality of life.

Oral cyclosporin doesn't stop hair loss.

This review summarizes existing medications for Polycystic Ovary Syndrome, highlighting herbal treatments, but does not report new clinical results.

This article discusses hyperandrogenism syndrome in women, highlighting systemic antiandrogenic therapy as advisable for severe or moderate hirsutism but reports no new clinical results.

This review found that antimalarial agents were more effective than steroids for Lichen planopilaris, while finasteride and dutasteride showed favorable impacts on frontal fibrosing alopecia, despite heterogeneous study quality.

The researchers reported finding 53 therapeutic and skincare products for hirsutism and hypertrichosis in Polish pharmacies and drugstores, identifying dienogest and cyproterone acetate as common active ingredients for hirsutism. They noted promising new treatments include eflornithine, acyclovir, licorice, and vitamin D.

This study found that patients using finasteride were up to twice as likely to experience sexual dysfunction, including ejaculation disorder, decreased libido, and impotence, compared to those not using the drug.

This study reported that estrogen-progestin oral contraceptives, antiandrogens, and insulin sensitizers are more effective than placebo in treating hirsutism in women, with combination therapies generally proving superior to monotherapy.

This study found that elagolix treatment did not normalize the ovulatory cycle in patients with polycystic ovarian syndrome.

This study found that Adiantum capillus-veneris extract exhibited significant antidepressant and anti-anxiety effects in rats, likely due to its antioxidant and anti-inflammatory properties.

Former finasteride users showed higher rates of depression and suicidal thoughts compared to those who never used it.

This study found that several drugs, including flutamide and spironolactone, significantly reduced hirsutism in women, with reduced effectiveness in those with higher BMI.

This review discusses post-finasteride syndrome, characterized by persistent symptoms despite discontinuation, and concludes that its existence cannot be confirmed; individualized assessment is advisable for those with a history of depression, sexual dysfunction, or infertility.

In this study, 1% pimekrolimus cream was found to be more effective than 0.05% clobetasol propionate for treating active plaques in patients with alopecia areata.

This study found that oral finasteride 1 mg/day promotes hair growth and prevents further hair loss in a significant proportion of men with male pattern hair loss over two years.

This article discusses the potential for severe adverse cutaneous drug reactions with mood-stabilizing agents, emphasizing the importance of monitoring and patient communication, but reports no new clinical findings.

This study concluded that topical ketoconazole is effective and safe for treating superficial fungal infections and has potential for new dermatologic uses despite concerns over oral administration's adverse effects.

This study found that the combination of cyproterone acetate and ethinyl estradiol improved hirsutism and acne in women, with SH 8.1041 showing significant results and both treatments being generally well-tolerated.

This clinical trial found that topical application of Sandalore® 1% significantly reduced hair shedding and increased hair volume in women with telogen effluvium compared to placebo.

This study found that a topical lotion containing minoxidil, hydrocortisone butyrate, and 17α-estradiol improved or stabilized frontal fibrosing alopecia in 35 out of 40 women over 36 months.

This study demonstrated that a 12-week treatment with luliconazole-containing shampoo significantly reduced scalp scaling, erythema, and itching in adults with seborrheic dermatitis, achieving high tolerability and progressive symptom improvement without reported intolerance or recurrences.

This report describes a case of hypozincemia type-II in an exclusively breast-fed infant, which resolved with zinc therapy and weaning, highlighting genetic factors in zinc transporter gene SLC30A2.

This review explores how psychotropic medications can cause a range of skin reactions, from mild to life-threatening, and emphasizes the importance of monitoring for these adverse effects early in treatment.

This article discusses challenges primary care physicians face in diagnosing and treating depression, noting that up to one-third of antidepressant prescriptions involve non-indicated use; it also introduces FDA-approved treatments, esketamine nasal spray, and brexanolone IV injection.

This study observed that patients with polycystic ovarian syndrome in a tertiary care hospital had a prevalence of 36% for anxiety and 16% for depression.

In this pilot study, both tofacitinib and methotrexate improved alopecia areata outcomes, but tofacitinib showed greater efficacy in achieving significant SALT score improvement after 6 months, although the difference was not statistically significant.

This article presents a collection of interdisciplinary studies by Brazilian researchers that address various societal issues to contribute to the nation's social and scientific development; it reports no new results.

This study found that preparing finasteride as a nanosuspension increased its aqueous solubility by more than 2.5 times, potentially enhancing drug bioavailability.

This abstract discusses the FitSpresso weight loss supplement's potential benefits and mechanisms but provides no clinical research findings; it reports on its ingredients and consumer ratings instead.